ARA-290 (Cibinetide) Research: What the Innate Repair Receptor Data Reveals

Written by: Dr. James Nguyen, MD (Neurosurgeon)

Erythropoietin (EPO) is best known for its role in red blood cell production. Over the past two decades, researchers have also documented a second role. EPO produced locally in tissue appears to protect cells from injury, and it does so through a different receptor from the one that drives red blood cell production. That finding raised an obvious question: could the tissue-protective activity be separated from the blood-producing activity?

ARA-290, also known as cibinetide, came out of that question. It is an 11-amino-acid peptide modeled on part of EPO’s three-dimensional structure. It is designed to engage the tissue-protective receptor without stimulating red blood cell production. This overview covers the mechanism, the preclinical research, and the small set of human trials that make ARA-290 one of the better-documented peptides in its category.

What Is ARA-290? From Erythropoietin to an 11-Amino-Acid Peptide

ARA-290 was developed by Michael Brines, Anthony Cerami, and colleagues, the group associated with Araim Pharmaceuticals. In a 2008 PNAS paper, they described how EPO’s two biological roles map onto two receptor arrangements [1]:

• Hematopoiesis (red blood cell production) runs through the classic EPO receptor homodimer.
• Tissue protection runs through a heterocomplex of the EPO receptor and CD131, the beta common receptor. This complex is now usually called the innate repair receptor (IRR).

The researchers traced the tissue-protective activity to helix B of the EPO molecule, the face that points away from the hematopoietic receptor. An 11-amino-acid peptide that mimics the water-facing surface of helix B kept tissue-protective activity in rodent models but was not erythropoietic in vitro or in vivo [1]. That peptide became ARA-290.

The design matters for research. Full-length EPO and its analogues carry known risks tied to their effects on blood cells, so a peptide that separates the two activities lets researchers study IRR signaling without that confounder [2].

“ARA-290 is a good example of structure-based peptide design: take a large protein, find the part that carries one specific function, and keep only that part.”

How ARA-290 Works: The Innate Repair Receptor Pathway

According to the Brines and Cerami model, the innate repair receptor is not active in healthy tissue all the time. It is upregulated in response to injury, metabolic stress, or inflammation [2]. Once engaged, IRR signaling is associated in preclinical work with:

• Cytoprotection: less apoptosis (programmed cell death) in tissue exposed to ischemia or other insults
• Anti-inflammatory signaling: reduced pro-inflammatory activity, including in spinal cord glial cells
• Tissue repair: support for wound healing and nerve fiber regeneration in animal models

The authors argue that the receptor’s injury-dependent expression may explain why its effects appear mainly in stressed or damaged tissue in these models [2].

What the Research Shows: Key Studies in ARA-290 Science

Preclinical foundation. In the original 2008 work, the helix B-derived peptides were protective in several rodent models, including ischemic stroke, diabetes-associated retinal edema, peripheral nerve trauma, and renal ischemia-reperfusion. The 11-amino-acid peptide was also reported to speed wound healing and affect cognitive measures in rodents [1].

Neuropathic pain models. A 2014 study in Molecular Pain used a spared nerve injury model in rats. It reported that ARA-290 reduced mechanical allodynia (pain sensitivity to normally non-painful touch) in a dose-dependent way, together with suppression of the spinal microglia response [3]. Microglial activation is thought to help sustain neuropathic pain, so this links IRR signaling to a well-studied pain mechanism.

Human phase 2 research. Unlike many research peptides, ARA-290 has been tested in several small, randomized, placebo-controlled human trials:

• Sarcoidosis-associated small fiber neuropathy (pilot, 2012): 22 patients took part in a double-blind exploratory trial. The ARA-290 group improved on a small fiber neuropathy symptom score relative to placebo, and no safety concerns were raised. Some other endpoints improved equally in both groups [4].
• Sarcoidosis follow-up (2013): A blinded, placebo-controlled 28-day trial reported improved neuropathic symptom scores. It also found increased corneal small nerve fiber density, measured with corneal confocal microscopy, a non-invasive way to image small nerve fibers, and better exercise capacity on the 6-minute walk test [5].
• Type 2 diabetes with painful neuropathy (2015): In a phase 2 study, participants receiving ARA-290 showed improvements in HbA1c, lipid profiles, and neuropathic symptom scores versus placebo. Corneal nerve fiber density increased in a subset of participants [6].
• Phase 2b sarcoidosis trial (2017): 64 subjects were randomized across several ARA-290 arms or placebo for 28 days. One ARA-290 group showed a statistically significant increase in corneal nerve fiber area, the primary endpoint, and changes correlated with a marker of regenerating skin nerve fibers and with walking-test performance [7].

Key Findings from ARA-290 Research

• Selective by design: The peptide mimics EPO’s tissue-protective surface and was not erythropoietic in the original models [1].
• Injury-responsive receptor: The innate repair receptor (EPOR/CD131) appears to be upregulated in stressed tissue [2].
• Glial modulation: Reduced allodynia in rat nerve-injury models was accompanied by suppression of spinal microglia [3].
• Human biomarker data: Several phase 2 trials reported changes in corneal nerve fiber measures, an objective structural endpoint [5][6][7].
• Tolerability in small trials: The published phase 2 studies reported no significant safety signals over short study periods [4][6].

What the Research Doesn’t Show Yet

The ARA-290 literature is more developed than most, but it has clear limits:

• The human trials are small and short, from about 22 to 64 participants, over roughly four weeks of exposure.
• Most clinical work was conducted by or with the developing company and its collaborators, so independent replication matters.
• Several endpoints were surrogate markers such as corneal nerve fiber measures. These are informative, but they are not the same as long-term clinical outcomes.
• ARA-290 is not FDA-approved for any indication.

Our guides on how to read a scientific paper and the role of peer review cover how to weigh small-trial data like these.

Explore ARA-290 and Related Research Peptides at BLL Peptides

BLL Peptides supplies research compounds that are third-party tested for identity and purity, with batch documentation available. Researchers studying tissue protection, inflammation, and repair signaling may find these relevant:

• ARA-290 10mg (10ml): EPO-derived innate repair receptor peptide for laboratory research
• BPC-157 10mg (3ml): pentadecapeptide studied in tissue repair models
• TB-500 10mg (3ml): Thymosin Beta-4 fragment studied in actin regulation and cell migration
• KPV 10mg (3ml): alpha-MSH-derived tripeptide studied in inflammation models

Related reading: BPC-157 Research Mechanisms · In Vitro vs. In Vivo Models · Understanding Certificates of Analysis

All products are intended for research purposes only and are not intended for human consumption.

Frequently Asked Questions About ARA-290 Research

Q: Is ARA-290 the same as cibinetide?
Yes. Cibinetide is the nonproprietary name for the peptide originally designated ARA 290. Both names appear in the literature [7].

Q: Does ARA-290 stimulate red blood cell production like EPO?
The original research found that the 11-amino-acid peptide was not erythropoietic in vitro or in vivo. Avoiding that activity was the main design goal [1].

Q: What is the innate repair receptor?
It is a receptor complex made of the EPO receptor and CD131 (the beta common receptor). It is associated with EPO’s tissue-protective effects and appears to be upregulated in injured or stressed tissue [1][2].

Q: Has ARA-290 been studied in humans?
Yes, in several small phase 2 randomized, placebo-controlled trials in sarcoidosis-associated small fiber neuropathy and type 2 diabetes with neuropathy. The trials were short and used surrogate endpoints, and the compound is not FDA-approved [4][5][6][7].

Q: How is ARA-290 different from BPC-157?
They are studied in overlapping tissue repair contexts but work through different proposed mechanisms. ARA-290 targets the EPOR/CD131 innate repair receptor. BPC-157 research centers on growth factor signaling, angiogenesis, and nitric oxide pathways.

References

1. Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA. 2008;105(31):10925-10930. https://pubmed.ncbi.nlm.nih.gov/18676614/
2. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med. 2008;264(5):405-432. https://pubmed.ncbi.nlm.nih.gov/19017170/
3. Swartjes M, van Velzen M, Niesters M, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain. 2014;10:13. https://pubmed.ncbi.nlm.nih.gov/24529189/
4. Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012;18:1430-1436. https://pubmed.ncbi.nlm.nih.gov/23168581/
5. Dahan A, Dunne A, Swartjes M, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013;19:334-345. https://pubmed.ncbi.nlm.nih.gov/24136731/
6. Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015;20:658-666. https://pubmed.ncbi.nlm.nih.gov/25387363/
7. Culver DA, Dahan A, Bajorunas D, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci. 2017;58(6):BIO52-BIO60. https://pubmed.ncbi.nlm.nih.gov/28475703/

This content is intended for research and educational purposes only. It is not medical advice. ARA-290 is not approved by the FDA for any human use. BLL Peptides products are not intended for human consumption.